Clinical momentum SightGlass Vision is actively sharing 24-month DOT spectacle data at ARVO 2026 and has forthcoming clinical rigor to support prescriber confidence, presenting a clear path for expanding clinician outreach and KOL engagement to drive adoption.

Strategic partnerships As a joint venture of CooperCompanies and EssilorLuxottica, SightGlass Vision benefits from established distribution channels and credibility, presenting sales opportunities through co-marketing, bundled products, and leveraging existing ophthalmic networks.

Global expansion Recent office expansion in Canada and broader North American outreach indicate a push into new regions, suggesting sales focus on international clinics and distributors to scale DOT spectacle adoption in ophthalmology practices.

Clinical affairs growth New hires in Clinical, Medical, and Professional Affairs signal emphasis on regulatory, clinical evidence, and professional education, creating opportunities to partner on studies, training programs, and prescriber education to accelerate market acceptance.

Awards and visibility Recognition as a Healthtech Company of the Year finalist and active participation at ophthalmology conferences provide marketing credibility and lead-generation potential through industry events, sponsorships, and targeted outreach to ARVO attendees and Optometry channels.